25 XP   0   0   10

PharmAust Ltd
Buy, Hold or Sell?

Let's analyse Pharmaust together

PenkeI guess you are interested in PharmAust Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of PharmAust Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about PharmAust Ltd

I send you an email if I find something interesting about PharmAust Ltd.

Quick analysis of Pharmaust (30 sec.)










What can you expect buying and holding a share of Pharmaust? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$-0.03
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
A$-0.04
Return On Investment
-12.5%

For what price can you sell your share?

Current Price per Share
A$0.32
Expected price per share
A$0.165 - A$0.535
How sure are you?
50%

1. Valuation of Pharmaust (5 min.)




Live pricePrice per Share (EOD)

A$0.32

Intrinsic Value Per Share

A$-0.04 - A$-0.01

Total Value Per Share

A$-0.03 - A$0.00

2. Growth of Pharmaust (5 min.)




Is Pharmaust growing?

Current yearPrevious yearGrowGrow %
How rich?$2.4m$5m-$2.5m-101.7%

How much money is Pharmaust making?

Current yearPrevious yearGrowGrow %
Making money-$3.9m-$1m-$2.8m-72.5%
Net Profit Margin-220.0%-50.5%--

How much money comes from the company's main activities?

3. Financial Health of Pharmaust (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#775 / 1016

Most Revenue
#400 / 1016

Most Profit
#472 / 1016

Most Efficient
#651 / 1016

What can you expect buying and holding a share of Pharmaust? (5 min.)

Welcome investor! Pharmaust's management wants to use your money to grow the business. In return you get a share of Pharmaust.

What can you expect buying and holding a share of Pharmaust?

First you should know what it really means to hold a share of Pharmaust. And how you can make/lose money.

Speculation

The Price per Share of Pharmaust is A$0.32. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharmaust.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharmaust, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharmaust.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-3.2%-0.01-3.2%0.00-0.9%0.00-1.2%0.00-1.1%
Usd Book Value Change Per Share-0.01-2.0%-0.01-2.0%0.00-0.5%0.00-0.3%0.000.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-2.0%-0.01-2.0%0.00-0.5%0.00-0.3%0.000.2%
Usd Price Per Share0.05-0.05-0.04-0.06-0.04-
Price to Earnings Ratio-4.76--4.76--16.16--20.46--14.72-
Price-to-Total Gains Ratio-7.48--7.48--26.64-34.29-24.74-
Price to Book Ratio7.60-7.60-3.52-4.87-4.34-
Price-to-Total Gains Ratio-7.48--7.48--26.64-34.29-24.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.205536
Number of shares4865
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.00
Gains per Quarter (4865 shares)-31.34-5.15
Gains per Year (4865 shares)-125.37-20.60
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-125-1350-21-31
20-251-2600-41-52
30-376-3850-62-73
40-501-5100-82-94
50-627-6350-103-115
60-752-7600-124-136
70-878-8850-144-157
80-1003-10100-165-178
90-1128-11350-185-199
100-1254-12600-206-220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%1.022.00.04.3%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%7.03.00.070.0%12.011.00.052.2%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.023.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%7.03.00.070.0%12.011.00.052.2%

Fundamentals of Pharmaust

About PharmAust Ltd

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

Fundamental data was last updated by Penke on 2024-04-12 14:30:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of PharmAust Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pharmaust earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Pharmaust to the Biotechnology industry mean.
  • A Net Profit Margin of -220.0% means that $-2.20 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of PharmAust Ltd:

  • The MRQ is -220.0%. The company is making a huge loss. -2
  • The TTM is -220.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-220.0%TTM-220.0%0.0%
TTM-220.0%YOY-50.5%-169.4%
TTM-220.0%5Y-84.2%-135.8%
5Y-84.2%10Y-92.4%+8.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-220.0%-197.2%-22.8%
TTM-220.0%-210.4%-9.6%
YOY-50.5%-279.3%+228.8%
5Y-84.2%-436.8%+352.6%
10Y-92.4%-599.3%+506.9%
1.1.2. Return on Assets

Shows how efficient Pharmaust is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharmaust to the Biotechnology industry mean.
  • -101.3% Return on Assets means that Pharmaust generated $-1.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of PharmAust Ltd:

  • The MRQ is -101.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -101.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-101.3%TTM-101.3%0.0%
TTM-101.3%YOY-16.9%-84.4%
TTM-101.3%5Y-32.5%-68.8%
5Y-32.5%10Y-30.8%-1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-101.3%-13.6%-87.7%
TTM-101.3%-12.9%-88.4%
YOY-16.9%-11.9%-5.0%
5Y-32.5%-14.2%-18.3%
10Y-30.8%-16.2%-14.6%
1.1.3. Return on Equity

Shows how efficient Pharmaust is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharmaust to the Biotechnology industry mean.
  • -159.7% Return on Equity means Pharmaust generated $-1.60 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of PharmAust Ltd:

  • The MRQ is -159.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -159.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-159.7%TTM-159.7%0.0%
TTM-159.7%YOY-21.8%-137.9%
TTM-159.7%5Y-47.0%-112.7%
5Y-47.0%10Y-40.7%-6.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-159.7%-17.0%-142.7%
TTM-159.7%-16.1%-143.6%
YOY-21.8%-15.4%-6.4%
5Y-47.0%-20.0%-27.0%
10Y-40.7%-21.1%-19.6%

1.2. Operating Efficiency of PharmAust Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharmaust is operating .

  • Measures how much profit Pharmaust makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharmaust to the Biotechnology industry mean.
  • An Operating Margin of -128.3% means the company generated $-1.28  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of PharmAust Ltd:

  • The MRQ is -128.3%. The company is operating very inefficient. -2
  • The TTM is -128.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-128.3%TTM-128.3%0.0%
TTM-128.3%YOY-81.3%-47.0%
TTM-128.3%5Y-90.1%-38.2%
5Y-90.1%10Y-84.5%-5.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-128.3%-286.1%+157.8%
TTM-128.3%-224.4%+96.1%
YOY-81.3%-288.4%+207.1%
5Y-90.1%-475.2%+385.1%
10Y-84.5%-624.7%+540.2%
1.2.2. Operating Ratio

Measures how efficient Pharmaust is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.28 means that the operating costs are $2.28 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of PharmAust Ltd:

  • The MRQ is 2.283. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.283. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.283TTM2.2830.000
TTM2.283YOY1.813+0.470
TTM2.2835Y1.939+0.344
5Y1.93910Y1.968-0.029
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2832.997-0.714
TTM2.2833.247-0.964
YOY1.8133.766-1.953
5Y1.9395.675-3.736
10Y1.9687.857-5.889

1.3. Liquidity of PharmAust Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharmaust is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.24 means the company has $2.24 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of PharmAust Ltd:

  • The MRQ is 2.242. The company is able to pay all its short-term debts. +1
  • The TTM is 2.242. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.242TTM2.2420.000
TTM2.242YOY3.200-0.958
TTM2.2425Y3.469-1.226
5Y3.46910Y3.662-0.193
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2423.930-1.688
TTM2.2424.251-2.009
YOY3.2005.436-2.236
5Y3.4696.045-2.576
10Y3.6626.363-2.701
1.3.2. Quick Ratio

Measures if Pharmaust is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharmaust to the Biotechnology industry mean.
  • A Quick Ratio of 2.17 means the company can pay off $2.17 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of PharmAust Ltd:

  • The MRQ is 2.173. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.173. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.173TTM2.1730.000
TTM2.173YOY2.255-0.081
TTM2.1735Y2.723-0.550
5Y2.72310Y3.134-0.411
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1733.629-1.456
TTM2.1734.065-1.892
YOY2.2555.397-3.142
5Y2.7235.993-3.270
10Y3.1346.277-3.143

1.4. Solvency of PharmAust Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharmaust assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharmaust to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.37 means that Pharmaust assets are financed with 36.6% credit (debt) and the remaining percentage (100% - 36.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of PharmAust Ltd:

  • The MRQ is 0.366. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.366. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.366TTM0.3660.000
TTM0.366YOY0.222+0.144
TTM0.3665Y0.223+0.142
5Y0.22310Y0.174+0.049
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3660.332+0.034
TTM0.3660.334+0.032
YOY0.2220.268-0.046
5Y0.2230.366-0.143
10Y0.1740.390-0.216
1.4.2. Debt to Equity Ratio

Measures if Pharmaust is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharmaust to the Biotechnology industry mean.
  • A Debt to Equity ratio of 57.6% means that company has $0.58 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of PharmAust Ltd:

  • The MRQ is 0.576. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.576. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.576TTM0.5760.000
TTM0.576YOY0.285+0.292
TTM0.5765Y0.302+0.275
5Y0.30210Y0.224+0.077
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5760.381+0.195
TTM0.5760.390+0.186
YOY0.2850.334-0.049
5Y0.3020.434-0.132
10Y0.2240.466-0.242

2. Market Valuation of PharmAust Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Pharmaust generates.

  • Above 15 is considered overpriced but always compare Pharmaust to the Biotechnology industry mean.
  • A PE ratio of -4.76 means the investor is paying $-4.76 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of PharmAust Ltd:

  • The EOD is -20.315. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.761. Based on the earnings, the company is expensive. -2
  • The TTM is -4.761. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-20.315MRQ-4.761-15.553
MRQ-4.761TTM-4.7610.000
TTM-4.761YOY-16.159+11.398
TTM-4.7615Y-20.458+15.697
5Y-20.45810Y-14.721-5.737
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-20.315-2.315-18.000
MRQ-4.761-2.560-2.201
TTM-4.761-2.664-2.097
YOY-16.159-4.122-12.037
5Y-20.458-6.258-14.200
10Y-14.721-6.108-8.613
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of PharmAust Ltd:

  • The EOD is -78.910. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -18.495. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -18.495. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-78.910MRQ-18.495-60.416
MRQ-18.495TTM-18.4950.000
TTM-18.495YOY-20.066+1.571
TTM-18.4955Y-44.209+25.714
5Y-44.20910Y-27.027-17.182
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-78.910-3.067-75.843
MRQ-18.495-3.251-15.244
TTM-18.495-3.545-14.950
YOY-20.066-5.595-14.471
5Y-44.209-8.315-35.894
10Y-27.027-8.708-18.319
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharmaust is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 7.60 means the investor is paying $7.60 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of PharmAust Ltd:

  • The EOD is 32.446. Based on the equity, the company is expensive. -2
  • The MRQ is 7.604. Based on the equity, the company is overpriced. -1
  • The TTM is 7.604. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD32.446MRQ7.604+24.841
MRQ7.604TTM7.6040.000
TTM7.604YOY3.519+4.086
TTM7.6045Y4.868+2.736
5Y4.86810Y4.338+0.530
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD32.4461.905+30.541
MRQ7.6042.111+5.493
TTM7.6042.095+5.509
YOY3.5192.836+0.683
5Y4.8683.443+1.425
10Y4.3383.794+0.544
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of PharmAust Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of PharmAust Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.010-0.0100%-0.003-74%-0.002-84%0.001-1205%
Book Value Per Share--0.0100.0100%0.020-50%0.019-47%0.018-44%
Current Ratio--2.2422.2420%3.200-30%3.469-35%3.662-39%
Debt To Asset Ratio--0.3660.3660%0.222+65%0.223+64%0.174+110%
Debt To Equity Ratio--0.5760.5760%0.285+102%0.302+91%0.224+157%
Dividend Per Share----0%-0%-0%-0%
Eps---0.016-0.0160%-0.004-72%-0.006-61%-0.005-66%
Free Cash Flow Per Share---0.004-0.0040%-0.003-14%-0.003-31%-0.004-10%
Free Cash Flow To Equity Per Share--0.0010.0010%-0.002+308%0.001-39%0.001-39%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.005--------
Intrinsic Value_10Y_min---0.038--------
Intrinsic Value_1Y_max---0.002--------
Intrinsic Value_1Y_min---0.004--------
Intrinsic Value_3Y_max---0.006--------
Intrinsic Value_3Y_min---0.011--------
Intrinsic Value_5Y_max---0.007--------
Intrinsic Value_5Y_min---0.019--------
Market Cap126185922.560+77%29574825.60029574825.6000%27603170.560+7%33833600.486-13%27889865.047+6%
Net Profit Margin---2.200-2.2000%-0.505-77%-0.842-62%-0.924-58%
Operating Margin---1.283-1.2830%-0.813-37%-0.901-30%-0.845-34%
Operating Ratio--2.2832.2830%1.813+26%1.939+18%1.968+16%
Pb Ratio32.446+77%7.6047.6040%3.519+116%4.868+56%4.338+75%
Pe Ratio-20.315-327%-4.761-4.7610%-16.159+239%-20.458+330%-14.721+209%
Price Per Share0.320+77%0.0750.0750%0.070+7%0.086-13%0.063+19%
Price To Free Cash Flow Ratio-78.910-327%-18.495-18.4950%-20.066+8%-44.209+139%-27.027+46%
Price To Total Gains Ratio-31.903-327%-7.477-7.4770%-26.643+256%34.292-122%24.736-130%
Quick Ratio--2.1732.1730%2.255-4%2.723-20%3.134-31%
Return On Assets---1.013-1.0130%-0.169-83%-0.325-68%-0.308-70%
Return On Equity---1.597-1.5970%-0.218-86%-0.470-71%-0.407-75%
Total Gains Per Share---0.010-0.0100%-0.003-74%-0.002-84%0.001-1205%
Usd Book Value--2497991.4112497991.4110%5038479.958-50%4701148.109-47%4642284.333-46%
Usd Book Value Change Per Share---0.006-0.0060%-0.002-74%-0.001-84%0.001-1205%
Usd Book Value Per Share--0.0060.0060%0.013-50%0.012-47%0.011-44%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.010-0.0100%-0.003-72%-0.004-61%-0.003-66%
Usd Free Cash Flow---1027107.068-1027107.0680%-883574.857-14%-706235.570-31%-1018196.954-1%
Usd Free Cash Flow Per Share---0.003-0.0030%-0.002-14%-0.002-31%-0.002-10%
Usd Free Cash Flow To Equity Per Share--0.0000.0000%-0.001+308%0.001-39%0.001-39%
Usd Market Cap81049218.060+77%18995910.48318995910.4830%17729516.451+7%21731321.592-13%17913660.319+6%
Usd Price Per Share0.206+77%0.0480.0480%0.045+7%0.055-13%0.041+19%
Usd Profit---3989684.988-3989684.9880%-1097182.641-72%-1577993.905-60%-1497806.668-62%
Usd Revenue--1813794.8241813794.8240%2171791.648-16%1954113.994-7%1715278.143+6%
Usd Total Gains Per Share---0.006-0.0060%-0.002-74%-0.001-84%0.001-1205%
 EOD+5 -3MRQTTM+0 -0YOY+6 -275Y+1 -3210Y+4 -29

4.2. Fundamental Score

Let's check the fundamental score of PharmAust Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-20.315
Price to Book Ratio (EOD)Between0-132.446
Net Profit Margin (MRQ)Greater than0-2.200
Operating Margin (MRQ)Greater than0-1.283
Quick Ratio (MRQ)Greater than12.173
Current Ratio (MRQ)Greater than12.242
Debt to Asset Ratio (MRQ)Less than10.366
Debt to Equity Ratio (MRQ)Less than10.576
Return on Equity (MRQ)Greater than0.15-1.597
Return on Assets (MRQ)Greater than0.05-1.013
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of PharmAust Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.302
Ma 20Greater thanMa 500.353
Ma 50Greater thanMa 1000.311
Ma 100Greater thanMa 2000.218
OpenGreater thanClose0.305
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets6,130
Total Liabilities2,241
Total Stockholder Equity3,889
 As reported
Total Liabilities 2,241
Total Stockholder Equity+ 3,889
Total Assets = 6,130

Assets

Total Assets6,130
Total Current Assets3,021
Long-term Assets3,109
Total Current Assets
Cash And Cash Equivalents 2,706
Short-term Investments 4
Net Receivables 214
Other Current Assets 97
Total Current Assets  (as reported)3,021
Total Current Assets  (calculated)3,021
+/-0
Long-term Assets
Property Plant Equipment 2
Intangible Assets 3,107
Other Assets 317
Long-term Assets  (as reported)3,109
Long-term Assets  (calculated)3,426
+/- 317

Liabilities & Shareholders' Equity

Total Current Liabilities1,347
Long-term Liabilities894
Total Stockholder Equity3,889
Total Current Liabilities
Short-term Debt 158
Accounts payable 926
Other Current Liabilities 263
Total Current Liabilities  (as reported)1,347
Total Current Liabilities  (calculated)1,347
+/- 0
Long-term Liabilities
Long term Debt Total 891
Other Liabilities 3
Long-term Liabilities  (as reported)894
Long-term Liabilities  (calculated)894
+/- 0
Total Stockholder Equity
Common Stock57,633
Retained Earnings -56,459
Accumulated Other Comprehensive Income 2,715
Total Stockholder Equity (as reported)3,889
Total Stockholder Equity (calculated)3,889
+/-0
Other
Capital Stock57,633
Cash and Short Term Investments 2,710
Common Stock Shares Outstanding 321,009
Current Deferred Revenue0
Liabilities and Stockholders Equity 6,130
Net Debt -1,657
Net Invested Capital 3,889
Net Tangible Assets 782
Net Working Capital 1,674
Property Plant and Equipment Gross 1,654
Short Long Term Debt Total 1,049



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-30
> Total Assets 
4,990
4,926
2,512
905
5,275
9,170
10,168
7,993
7,570
6,828
1,451
2,409
905
8,210
9,522
6,257
8,195
8,358
8,596
10,746
10,954
10,078
6,130
6,13010,07810,95410,7468,5968,3588,1956,2579,5228,2109052,4091,4516,8287,5707,99310,1689,1705,2759052,5124,9264,990
   > Total Current Assets 
2,379
1,879
686
348
1,940
1,786
997
7,395
6,927
4,155
368
358
442
2,452
3,732
1,330
3,344
2,756
3,020
4,070
4,357
3,731
3,021
3,0213,7314,3574,0703,0202,7563,3441,3303,7322,4524423583684,1556,9277,3959971,7861,9403486861,8792,379
       Cash And Cash Equivalents 
1,912
930
624
182
785
329
272
817
3,800
2,753
86
123
363
2,304
3,412
882
2,590
1,875
2,091
2,880
3,020
2,416
2,706
2,7062,4163,0202,8802,0911,8752,5908823,4122,304363123862,7533,8008172723297851826249301,912
       Short-term Investments 
0
0
0
0
0
0
0
3,387
78
131
9
6
2
9
11
4
4
6
4
4
4
4
4
44444644119269131783,3870000000
       Net Receivables 
467
949
62
166
784
936
199
110
349
236
272
228
73
104
287
118
259
248
259
311
262
204
214
2142042623112592482591182871047322827223634911019993678416662949467
       Other Current Assets 
0
0
0
0
67
42
46
3,081
2,700
1,034
1
0
4
36
21
4
8
59
59
17
63
64
97
9764631759598421364011,0342,7003,0814642670000
   > Long-term Assets 
2,611
3,047
1,827
557
3,335
7,383
9,171
598
643
2,673
1,083
2,051
464
5,758
5,790
4,927
4,851
5,602
5,576
6,676
6,597
6,347
3,109
3,1096,3476,5976,6765,5765,6024,8514,9275,7905,7584642,0511,0832,6736435989,1717,3833,3355571,8273,0472,611
       Property Plant Equipment 
543
611
289
429
3,100
6,994
3,448
579
643
2,673
604
2,051
464
578
611
1,820
1,744
2,494
2,468
3,569
3,455
3,238
2
23,2383,4553,5692,4682,4941,7441,8206115784642,0516042,6736435793,4486,9943,100429289611543
       Goodwill 
96
76
56
119
0
0
577
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000057700119567696
       Intangible Assets 
1,972
1,760
1,408
119
157
387
577
0
0
0
0
0
0
5,179
5,179
3,107
3,107
3,107
3,107
3,107
3,142
3,110
3,107
3,1073,1103,1423,1073,1073,1073,1073,1075,1795,1790000005773871571191,4081,7601,972
       Other Assets 
0
0
1,062
0
0
0
91
0
0
0
479
0
0
0
0
0
0
0
0
0
0
0
317
31700000000000479000910001,06200
> Total Liabilities 
980
1,456
698
164
1,406
1,483
2,333
2,078
1,714
1,020
303
1,196
595
445
683
1,234
1,280
1,220
1,140
2,220
2,073
2,234
2,241
2,2412,2342,0732,2201,1401,2201,2801,2346834455951,1963031,0201,7142,0782,3331,4831,4061646981,456980
   > Total Current Liabilities 
289
587
698
143
1,350
1,252
2,209
2,078
1,714
984
298
1,117
504
406
664
735
956
1,193
922
1,058
911
1,166
1,347
1,3471,1669111,0589221,1939567356644065041,1172989841,7142,0782,2091,2521,350143698587289
       Short-term Debt 
0
0
432
17
232
135
1,435
1,376
1,376
28
31
595
2
32
32
158
206
425
143
355
147
348
158
1583481473551434252061583232259531281,3761,3761,4351352321743200
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
71
39
150
206
425
143
179
38
210
0
02103817914342520615039710000000000000
       Accounts payable 
131
257
261
126
1,038
880
5,064
631
276
864
188
440
420
230
460
397
362
617
739
557
559
604
926
9266045595577396173623974602304204401888642766315,0648801,038126261257131
       Other Current Liabilities 
158
330
6
0
79
237
167
72
62
93
79
82
84
144
173
180
388
152
40
147
206
214
263
263214206147401523881801731448482799362721672377906330158
   > Long-term Liabilities 
691
869
0
21
57
232
124
0
0
36
5
79
90
39
19
499
324
27
218
1,162
1,162
1,068
894
8941,0681,1621,16221827324499193990795360012423257210869691
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
450
281
1
181
1,117
1,131
1,037
891
8911,0371,1311,1171811281450800000000000000
       Long term Debt 
651
868
0
21
57
232
4,473
0
0
36
5
0
0
39
8
450
281
1
181
38
0
0
0
00038181128145083900536004,47323257210868651
       Capital Lease Obligations Min Short Term Debt
0
0
-432
-17
-232
-135
-1,435
-1,376
-1,376
-28
-31
-595
-2
-32
-32
-150
-206
-425
-143
900
1,093
827
891
8918271,093900-143-425-206-150-32-32-2-595-31-28-1,376-1,376-1,435-135-232-17-43200
       Other Liabilities 
39
0
0
0
0
0
9
0
0
0
0
79
90
0
11
49
43
26
37
45
30
31
3
3313045372643491109079000090000039
> Total Stockholder Equity
4,010
3,470
1,814
659
3,868
7,686
7,835
5,914
5,857
5,807
1,148
1,213
311
7,764
8,839
5,023
6,915
7,138
7,456
8,526
8,880
7,844
3,889
3,8897,8448,8808,5267,4567,1386,9155,0238,8397,7643111,2131,1485,8075,8575,9147,8357,6863,8686591,8143,4704,010
   Common Stock
6,105
9,270
9,688
11,080
17,653
21,138
24,387
27,691
28,043
27,865
29,004
33,329
32,942
41,393
44,393
44,463
47,605
49,371
51,388
53,772
55,326
55,344
57,633
57,63355,34455,32653,77251,38849,37147,60544,46344,39341,39332,94233,32929,00427,86528,04327,69124,38721,13817,65311,0809,6889,2706,105
   Retained Earnings -56,459-50,247-48,539-47,202-45,906-44,289-41,767-40,423-36,496-34,571-33,253-32,738-28,478-22,680-22,499-22,825-17,057-16,393-13,785-10,421-7,874-5,800-2,094
   Accumulated Other Comprehensive Income 
-102
-319
-423
-142
-123
2,942
506
1,049
313
622
622
622
622
942
942
983
1,077
2,055
1,907
1,956
2,093
2,748
2,715
2,7152,7482,0931,9561,9072,0551,0779839429426226226226223131,0495062,942-123-142-423-319-102
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
102
319
0
0
0
0
0
0
0
0
0
0
0
942
942
983
1,077
2,055
66
-6,571
0
-5,097
-1,174
-1,174-5,0970-6,571662,0551,07798394294200000000000319102



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.